ArticleJournal of translational medicine2026
Upregulation of CSN8 induces a unique senescence-like state with robust tumor-promoting properties in epithelial ovarian cancer cells under hypoxia.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEpithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence. Cellular senescence is widely involved in cancer tumor relapse and metastasis. Hypoxia has a profound impact on malignant progression and participates in modulating senescence; however, the mechanism of inducing senescence by hypoxia in EOC is unclear.
methodsTissue microarrays and immunohistochemistry were used to assess the expression of CSN8 and CD47 in EOC tissues. Tissue microarrays and multiplex fluorescent immunohistochemistry were used to analyze the expression of CSN8, p16, CD68 and CD206 in EOC tissues. The regulatory effects of CSN8 on the senescence of EOC cells were evaluated by EdU, CCK-8, SA-β-gal staining, transwell, ELISA and flow cytometry assays. To investigate the underlying mechanism in regulating senescence by CSN8 in EOC cells, real-time PCR, immunoprecipitation and Western blot assays were utilized. Transplanted tumor models of mice were used to study the antitumor effects of targeting CSN8 combined anti-CD47 therapy.
resultsCSN8 expression is upregulated in EOC tissues, and CSN8-overexpressed EOC cells exhibit senescence-like features (increased SA-β-gal activity, p16 expression, and SASP production) and robust tumor-promoting properties. An increase in CSN8 + p16+EOC cells in primary tumor tissues correlates with EOC stage, invasion depth, distant metastasis, poor overall survival, and relapse. Furthermore, CSN8-mediated senescence-like EOC cells display unique features, including low ROS production; low p21 expression; low DDR activation; low CD47 expression; and high resistance to senolytic drugs. CSN8 promotes senescence-like EOC cell survival and induces reversible growth arrest by eliminating excessive ROS. These cells shape the immunosuppressive tumor microenvironment by promoting macrophage recruitment and M2-like polarization. CSN8 silencing enhanced sensitivity to chemotherapy and senolytic drugs, and improved the therapeutic effects of anti-CD47 antibody. CSN8 enhanced HIF-1α protein expression and suppressed Skp2 and p21 expression through inhibiting HIF-1α ubiquitination, and promoting Skp2 and p21 ubiquitination, thereby mediating a hypoxia-induced senescence-like state.
conclusionsOur studies demonstrated a novel mechanism of inducing a senescence-like state in EOC cells mediated by CSN8 under hypoxia, which correlates with EOC relapse and metastasis. CSN8 + p16+ EOC cells could be exploited as a novel prognostic biomarker for EOC. CSN8 would be an ideal target to eliminate senescence-like tumor cells for treating EOC relapse and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.